Evidence digest
What the research on NAD+ actually shows
The indexed literature on NAD+ includes human clinical or observational records (4 human-clinical or observational records). This digest describes the shape of that evidence and links the records behind it. It does not judge whether NAD+ is safe or effective for any purpose, and nothing here is medical advice — the material sold by the vendors in this index is labeled for laboratory research use only.
Updated 25 Aug 2026 · 4 studies indexed · 4 human · compound record
- Studies indexed
- 4
- Human evidence
- 4
- Preclinical only
- 0
What is and is not established
What the literature supports
- Human clinical or observational records are indexed for NAD+ (4).
- Published research is indexed back to 1980, with roughly 62,478 PubMed records located.
- It is listed by one or more vendors tracked in this index.
What is NOT established
- This index does not evaluate whether NAD+ is safe or effective for any use.
- Material sold by the vendors indexed here is labeled for laboratory research use only and is not a regulator-approved medicine in that form.
- No dosing, protocol or human-use guidance is provided or implied anywhere in this index.
Studies indexed
3 human — controlled trial · 1 systematic review
| Study | Evidence type | Model | n | What it reported | Source |
|---|---|---|---|---|---|
| The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trialGeroScience · 2023 | Human — controlled trial | Not recorded | — | In animal studies, β-nicotinamide mononucleotide (NMN) supplementation increases nicotinamide adenine dinucleotide (NAD) concentrations and improves healthspan and lifespan with great safety. However, it is unclear if these effects can be transferred to humans. This randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial included 80 middle-aged healthy adults being randomized for a 60-day clinical trial with once daily or… | PMID 36482258 |
| Evaluation of safety and effectiveness of NAD in different clinical conditions: a systematic reviewAmerican journal of physiology. Endocrinology and metabolism · 2024 | Systematic review | Not recorded | — | Nicotinamide adenine dinucleotide (NAD+) is an essential pyridine nucleotide cofactor that is present in cells and in several important biological processes, including oxidative phosphorylation and production of adenosine triphosphate, DNA repair, calcium-dependent secondary messenger and gene expression. The purpose of this systematic review is to examine whether the coenzyme formulae NAD+ and NADH are safe and effective when acting as a supplement to humans. This systematic… | PMID 37971292 |
| Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic womenScience (New York, N.Y.) · 2021 | Human — controlled trial | Not recorded | — | In rodents, obesity and aging impair nicotinamide adenine dinucleotide (NAD+) biosynthesis, which contributes to metabolic dysfunction. Nicotinamide mononucleotide (NMN) availability is a rate-limiting factor in mammalian NAD+ biosynthesis. We conducted a 10-week, randomized, placebo-controlled, double-blind trial to evaluate the effect of NMN supplementation on metabolic function in postmenopausal women with prediabetes who were overweight or obese. Insulin-stimulated glucos… | PMID 33888596 |
| Zinc promotes microbial p-coumaric acid production that protects against cholestatic liver injuryCell host & microbe · 2024 | Human — controlled trial | Not recorded | — | Cholestatic liver disease (CLD) is a common liver disorder with limited treatment options. Here, we demonstrate that zinc (Zn) supplementation can alter the gut microbiome to mitigate cholestatic liver injury. Oral Zn altered the microbiota of mice and humans (this study was registered at clinicaltrials.gov [NCT05597137]), increasing the abundance of Blautia producta (B. producta) and promoting the generation of p-coumaric acid. Additionally, p-coumaric acid concentratio… | PMID 39610253 |
Vendors listing NAD+
The evidence above describes the published literature. What any individual vial contains is a separate question, answered by that vendor’s certificate records rather than by any study on this page.
| Vendor | Score · Coverage | Certificates | |
|---|---|---|---|
| Curo | 93.877% | 3 | profile → |
| Polaris Peptides | 93.877% | 1 | profile → |
| Next Gen Peptides | 93.897% | 2 | profile → |
| Amino Club | 90.495% | 0 | profile → |
| Ascend Science | 90.291% | 2 | profile → |
| Prime Peptides | 87.180% | 1 | profile → |
| American Peptides | 83.6100% | 2 | profile → |
| Origin Labs | 81.885% | 1 | profile → |
| Northline Labs | 79.493% | 1 | profile → |
| ZC Labs | 79.384% | 3 | profile → |
| Ascension Peptides | 78.186% | 1 | profile → |
| Vertex Labs | 70.170% | 1 | profile → |
| Improved Peptides | 7089% | 0 | profile → |
| Disguised Alpha | 69.150% | 0 | profile → |
| Eternal Peptides | 68.265% | 0 | profile → |
| BioLongevity Labs | 67.274% | 0 | profile → |
| Evolve Peptides | 65.567% | 0 | profile → |
| Mile High Compounds | 65.494% | 0 | profile → |
How to read this page
This digest describes what published research exists and what it does not establish. It is not a recommendation, contains no dosing information or protocols, and makes no claim that any compound is safe or effective for any purpose. Material listed by indexed vendors is labeled for laboratory research use only.